Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2022 | Story Anthony Mthembu | Photo Sonia Small
UFS students

The University of the Free State realises that the registration period can be stressful and frustrating to students for various reasons. 

In an effort to ensure that as many students as possible can successfully register for the 2022 academic year, the University of the Free State (UFS) has introduced a number of financial concessions. These financial concessions are specifically intended to fast-track the registration process of students who are currently awaiting confirmation of funding from the National Student Financial Aid Scheme (NSFAS).

Students with challenges regarding the application of the N+ rule

Students who have previously registered for foundation programmes and those who have continued with mainstream programmes will be allowed to register without the prerequisite of a first payment. This is on condition that they apply with the N+ rule (an added year of funding) and that their respective foundation programmes are included in the Department of Higher Education and Training (DHET)-funded list. Only students who do not have outstanding debt will qualify for this concession. 

2022 NSFAS-funded students

In addition, students whose funding has been confirmed by NSFAS for the 2022 academic year, will be permitted to register without a first payment.

Students without NSFAS 2022 funding confirmation with outstanding debt

Students awaiting NSFAS funding confirmation for 2022 will be allowed to register provisionally if their debt does not exceed R25 000.
Approval has been obtained to increase the maximum debt carried forward from 2021 from R20 000 to R25 000 to enable students to register provisionally.

Provisional registration for continuing NSFAS students 

Furthermore, continuing NSFAS students who are currently awaiting funding confirmation for the 2022 academic year, will be permitted to register provisionally. These are students
• who have been funded by NSFAS in 2021; 
• whose funding reflects on the NSFAS Bursary Agreement Report for the year 2021; and
• who have passed 50% of registered modules in 2021 or are in their final year in 2022. 
• The offer for continuing students to register provisionally also extend to those who are in the N+1 period. 

The official registration of these students will be subject to funding approval from NSFAS for the 2022 academic year. To ensure that all students are in classes on 21 February 2022, the abovementioned group of students have until 31 March 2022 to confirm their funding. 

Conditional registration for first-time entering students

With registration an overwhelming experience for first-time entering students, the UFS is also looking at concessions for these students who will start their studies at the university this year. 

The university has given first-time entering students who have applied for NSFAS funding and are awaiting confirmation, until 28 February 2022 to finalise their registration. 

Permission to finalise registration a week after the UFS registration cut-off time is granted to all South African first-time entering undergraduate students who are admitted and term-activated for 2022 NSFAS-funded academic programmes, and whose funding has not yet been confirmed. 

The amount payable for conditional registration for first-time entering students (residential and non-residential) is R500.

The UFS is hopeful that these financial concessions will assist in calming anxiety around the ongoing registration process.


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept